Anti-cancer drug bexarotene (Tagretin), which had extremely promising results in reversing Alzheimer's disease symptoms in mice last year, was found not to be as promising in later trials, according to articles published in the journal Science. In other words, scientists have not able to fully replicate the original findings. Last year, researchers from Case Western Reserve University claimed that bexarotene cleared amyloid plaques from the brains of transgenic laboratory mice...
More...
More...